Glicopepton

Glicopepton Biotech is a strategic biotechnology project born from the collaboration between Càrniques Celrà, Costa Food Group, and Laboratorios Farmacéuticos ROVI, with the aim of developing solutions of high technological, sanitary, and nutritional value from pork by-products, integrating innovation, sustainability, and industrial excellence.

The initiative is a clear example of applied circular economy, as it enables the transformation of pig intestinal mucosa into heparin, an essential anticoagulant medicine for the prevention and treatment of thromboembolic diseases. This is a biologically derived drug, critical for healthcare systems, and producing it nationally represents a significant advance in terms of health safety, industrial autonomy, and technological capability.

One of the main objectives of Glicopepton Biotech is to contribute to the self-sufficiency of heparin in Spain, reducing external dependence and strengthening the pharmaceutical supply chain. We are proud to produce this medicine with the highest sanitary guarantees and complete traceability, from the origin of the raw material to the final product, complying with the strictest quality, control, and safety standards required by the pharmaceutical industry.

In addition, the project promotes the full valorization of by-products generated during the production process. Materials not used for heparin production are transformed into highly nutritious animal feed and fertilizers, contributing to efficient resource use, waste reduction, and a more sustainable and environmentally responsible production model.

Glicopepton Biotech brings together the expertise of Laboratorios Farmacéuticos ROVI, an international benchmark in research and development of low molecular weight heparins, the leadership of Costa Food Group as one of Europe’s leading pork producers, and the knowledge and specialization of Càrniques Celrà in the meat sector. This combination of capabilities allows the development of an innovative project that generates economic, technological, and social value, while promoting skilled employment, research, and industrial development in the region.

With Glicopepton Biotech, Càrniques Celrà reaffirms its commitment to innovation, sustainability, health safety, and excellence, actively participating in an initiative that positions the meat industry as a key player in the development of high-impact biotechnological solutions for society.